Regenerative Medicine and Stem Cells Technologies

Key Biologics LLC, a provider of biological raw materials and services for manufacturing cell-based therapeutics, today announced the availability of fresh and frozen whole leukaphereses from patients with hematologic malignancies; Multiple Myeloma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Acute Lymphocytic Leukemia.

Immunotherapy has given patients and oncologists new options, which for some patients, has meant cures for diseases that had been untreatable.

NIH-funded researchers at Stanford University used the gene editing tool CRISPR-Cas9 to rapidly identify genes in the human genome that might modify the severity of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by mutations in a gene called C9orf72. The results of the search, published in Nature Genetics, uncovered a new set of genes that may hasten neuron death during the disease.

Scientists have used the breakthrough gene-editing technology CRISPR to create advances in medicine and agriculture, from ways to eliminate sickle-cell anemia to growing mushrooms that resist browning.

This week, Jack Nicklaus spoke up about an experimental treatment he underwent in Germany in 2016 in an effort to soothe his lifelong back pain. In a conversation with CNN, the Golden Bear shared details of the stem cell therapy he believes helped to ease the pain that has long plagued him, especially when playing golf.

The provision of blood for patients who require repeated blood transfusions, as well as for individuals with rare blood types, presents an enormous challenge to transfusion services worldwide. While most people can safely receive a blood transfusion from donated blood, patients with blood disorders such as thalassemia or sickle cell disease require frequent transfusions.

The Director of Neurogen Brain and Spine Institute, India, Dr. Alok Sharma, has described the Stem Cell Therapy as a ray of hope for victims of neurological disorders.

A long-term study of patients who received stem cells to treat angiitis-induced critical limb ischemia (AICLI) shows the cells to be both safe and effective. The study, published in Stem Cells Translational Medicine (SCTM), could lead to an option for those who suffer from this serious form of peripheral arterial disease (PAD

Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury.

CRISPR-Cas13 is an RNA editing technique that can alter protein sequences without modifying the genome in a cell. Recent advances in CRISPR-Cas13 technology mean that it can now be used to locate and even reduce cancer associated gene expression.